med onc @JHBreastGyn @HopkinsKimmel @HopkinsMedicine, @JohnsHopkins professor, @CLOSLER member. @ASCO fellow. @NCICTEP_ClinRes. @SusanGKomen scholar š§š·/šŗš²
Joined April 2008
- Tweets 2,613
- Following 3,123
- Followers 3,448
- Likes 5,660
85 Photos and videos
Pinned Tweet
Why #ClinicalTrials? Because they matter. They help us develop the best interventions & treatments, and often ensure patients receive the best possible care. #BCSM #ItTakesAVillage @JHBreastGyn @hopkinskimmel
12 Oct 2022
October is #breastcancerawarenessmonth. @awolff from @hopkinskimmel explains the benefit of clinical trials to both patients undergoing treatment and those who will be diagnosed in the future. #bcsm
1
4
33
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
Donāt miss Dr. Erica Mayer (@elmayermd) presenting results from a Phase II study on neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated #BreastCancer, focusing on the ER /HER2- cohort, at the #SABCS24 Rapid Fire 3 session. @TheTBCRC
šļø Friday, December 13th
ā° 12:00 ā 12:50 pm CST (1:00 ā 1:50 pm EST)
š Hall 1
1
5
13
2,212
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
10 Dec 2024
#SABCS24
Dr. @awolff: Must study impact of new #cancer drugs on reproductive health.
āļø He believes we are under-utilizing ovarian suppression & over-utilizing chemo in premenopausal w/ #breastcancer, & window to answer this Q definitively in #bcsm #clinicaltrials is closing.
6
12
1,485
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
10 Nov 2024
Excited to see these @TheTBCRC presentations at SABCS 2024!
-TBCRC 052: Does margetuximab provide benefit over trastuzumab in neoadjuvant HER2 disease?
-TBCRC 056: neoadjuvant PARP IO in ER BRCA1/2 or PALB2 mut breast cancer?
- and more!
2
7
2,997
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
12 Apr 2024
We are excited to have this trial open for patients with #metastatic #breastcancer treated an NCI community oncology practices #NCORP
@eaonc @awolff @ruthcarlosmd @ilana_graetz @LynneWagnerPhD
12 Apr 2024
#ClinicalTrial EAQ221CD/CONCURxP monitors CDK4/6 inhibitor medication use with text message reminders & alerts for patients treated for #BreastCancer. For more information: bit.ly/EAQ221CD #bcsm cc: @GelarehSadigh, @ilana_graetz
4
13
2,156
It was a treat to do the Highlights of the Day I - Breast Ca Metastatic, and contextualize the great work of presenters and discussants. Thou shalt not forget to watch the fantastic talk by discussant @MayoClinic Dr. Ciara O'Sullivan.
1 Jun 2024
Taking a moment to acknowledge that many places, especially in third world countries, lack access to essential drugs and resources. We are fortunate to have more in the US.
A shout out to Dr. OāSullivan for acknowledging that treatment paradigms are not applicable everywhere, we often take that for granted ā¼ļø
#HealthEquity #AccessToCare #ASCO24 #bcsm
@MayoCancerCare @ASCO @OncoAlert
4
25
5,682
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
3 Jun 2024
RxPONDER: AMH (low levels associated w/ diminished ovarian reserve) in women classified as premenopausal
If low AMH --> no benefit from adj chemo
If med/high AMH--> ā¬ļø4.4% in 5 yr DRFS w/ chemo
Suggests:chemo impact may be due to impact on ovarian fxn
@OncoAlert #ASCO24
34
93
8,014
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
Dr. Nadine Tung discusses TBCRC048 at #ASCO24 - olaparib is effective in patients with MBC with inherited PALB2 mutation or tumor acquired BRCA1 or BRCA2 mutation. Benefit in initial trial confirmed in a larger group of patients @TheTBCRC @OncoAlert
7
20
21,379
So grateful, @TarahBallinger. We are privileged that you chose to bring your brilliance to @eaonc and brighten the work we do to improve care for our patients. @NCICancerCtrl #ASCO24
Tarah, your presentation was just fantastic, and your work a true testament to your passion, commitment and skill. I am honored to work with you. Canāt wait to see what you will do next!!
3
6
967
#TrialsThatImpactPatientCare Congratulations to the @eaonc EAZ171 Team! #ASCO24 See full press release ecog-acrin.org/press-releaseā¦ and simultaneous JCO paper ascopubs.org/doi/10.1200/JCOā¦
3 Jun 2024
Check out @JCO_ASCO Podcast: "EAZ171: Predictors of TIPN in Black women with #BreastCancer" w/ Dr. @ShannonWestin & Dr. @BryanSchne90417. EAZ171 was presented at the #ASCO24 Annual Meeting.
@TarahBallinger @NCIprevention #NCORP @SusanGKomen @VBFoundation jcopodcast.libsyn.com/eaz171ā¦
3
4
1,052
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
ETHAN - groundbreaking new @TheTBCRC trial for male breast cancer led by PI Dr. Pablo Leone. #ASCO24
Learn more at classic.clinicaltrials.gov/cā¦
5
14
915
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
3
10
520
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
PI Dr. Tiffany Traina presenting the actively enrolling TBCRC058 trial #ASCO24 @RitaNandaMD
Find more info at: classic.clinicaltrials.gov/cā¦
1
2
245
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
2 Jun 2024
Tomorrow #ASCO24 check out @NTungMD present #TBCRC048 olaparib expanded cohorts of gPALB2 and sBRCA MBC, one of the most rewarding studies Iāve managed in the last decade and a testament to the power of investigator-initiated research @BIDMChealth @DFCI_BreastOnc @TheTBCRC
2
8
986
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
2 Jun 2024
TBCRC048 is a collaborative IST led by #DFHCC and was open at 11 academic centers across the US via @TheTBCRC - thank you to the incredibly dedicated study teams at each of the sites and, most importantly, the 114 participants, many of whom traveled great distances for the study
2 Jun 2024
Tomorrow #ASCO24 check out @NTungMD present #TBCRC048 olaparib expanded cohorts of gPALB2 and sBRCA MBC, one of the most rewarding studies Iāve managed in the last decade and a testament to the power of investigator-initiated research @BIDMChealth @DFCI_BreastOnc @TheTBCRC
2
5
611
Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) retweeted
As seen today at #ASCO24 - TBCRC026, HER2-E and tumors with increased immune signaling more likely to respond to HER2-directed therapy in ER-/HER2 breast cancer treated with neoadjuvant HP without chemo. @TheTBCRC @HennessyMaeve
7
21
3,826
2 Jun 2024
TBCRC 049: Tucatinib, trastuzumab, capecitabine for HER2 LMD
-The first prospective LMD trial to show all of the following:
-therapeutic drug levels in CSF
-intracranial response
-improvement in symptoms and QoL
-extended OS compared to historical controls
2
10
1,300
This is what qualifies for an oncologist to be in the presence of a rock star ā¦ā¦@NIHDirectorā© ! #asco24 ā¦@judywawiraā© ā¦@RamalingamMDā©
1
4
15
1,502
Training & Promoting the next generation of breast cancer leaders, and of course designing the next generation of trials to improve patient outcomes.
2
431
What a trio of ACRA Award recipients, including @hopkinskimmel @JHBreastGyn Cesar Santa-Maria, MD! Congratulations to all in the Class of #ASCO24 @ConquerCancerFd awardees and their mentors! @ASCO
2
6
21
927